Key result
Sarecycline binds to the bacterial 70S ribosome with its unique C7 moiety extending into the mRNA channel to directly interact with the A-site codon, acting as a potent translation initiation inhibitor.
Structural and biochemical analyses reveal that sarecycline's unique C7 extension interacts directly with mRNA on the 70S ribosome, explaining its potent inhibition of translation initiation.
Answers are grounded in this paper and cite their sources.
Sarecycline may confer differentiated activity; leaves open mRNA-channel targeting for next-generation antibiotics.
70S ribosome. Our 2.8-Å resolution structure revealed that sarecycline binds at the canonical tetracycline binding site located in the decoding center of the small ribosomal subunit. Importantly, unlike other tetracyclines, the unique C7 extension of sarecycline extends into the messenger RNA (mRNA) channel to form a direct interaction with the A-site codon to possibly interfere with mRNA movement through the channel and/or disrupt A-site codon-anticodon interaction. Based on our biochemical studies, sarecycline appears to be a more potent initiation inhibitor compared to other tetracyclines, possibly due to drug interactions with the mRNA, thereby blocking accommodation of the first aminoacyl transfer RNA (tRNA) into the A site. Overall, our structural and biochemical findings rationalize the role of the unique C7 moiety of sarecycline in antibiotic action.
No takes yet. Share an insight, caveat, or question.
Batool et al. (2020) studied this question. Sarecycline vs. Tetracycline was evaluated. Sarecycline binds to the bacterial 70S ribosome with its unique C7 moiety extending into the mRNA channel to directly interact with the A-site codon, acting as a potent translation initiation inhibitor.
Synapse has enriched 10 related papers. Consider them for comparative context: